◎ Sugi Atlas

Atlas / Disease / Arthritic joint disease

Arthritic joint disease

disease
On this page

Also known as arthritisinflammation of skeletal jointinflammatory disorder of jointskeletal joint inflammation

Summary

Arthritic joint disease (MONDO:0005578) is a disease (an umbrella term covering 13 Mondo subtypes) with 3 cohort genes (20 GWAS associations across 54 studies) and 329 clinical trials. Top therapeutic interventions include sumatriptan, adalimumab, and betamethasone.

At a glance

  • Umbrella term: 13 Mondo subtypes
  • Cohort genes: 3
  • GWAS associations: 20
  • ClinVar variants: 7
  • Clinical trials: 329

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namearthritic joint disease
Mondo IDMONDO:0005578
EFOEFO:0005856
MeSHD001168
DOIDDOID:848
NCITC2883
SNOMED CT3723001
UMLSC0003864
MedGen2043
Is cancer (heuristic)no

Also known as: arthritis · inflammation of skeletal joint · inflammatory disorder of joint · skeletal joint inflammation

Data availability: 7 ClinVar variants · 20 GWAS associations (54 studies).

Disease family

An umbrella term covering 13 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › bone disorder › bone inflammation disease › arthritic joint disease

Related subtypes (5): mastoiditis, epicondylitis, Osgood-Schlatter disease, osteomyelitis, Caffey disease

Subtypes (13): chondrocalcinosis, transient arthritis, synovitis, osteoarthritis, periarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, reactive arthritis, adult-onset Still disease, polyarticular arthritis, infective arthritis, negative rheumatoid factor polyarthritis, hemophilic arthropathy

Genetics & variants

GWAS landscape

20 GWAS associations across 54 studies. Top hits map to 5 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs731848808e-12NKILA - LINC01742G2.42
rs1903949169e-12SLIT1C3.85
rs5701604661e-11MICA-AS1C0.15
rs5608193784e-11RN7SL336P - SRSF12A1.68
chr2:704918889e-11G0.05
chr8:175741332e-09T2.53
rs765252221e-08TDRD9?
chr18:280757642e-08C1.81
chr3:500607532e-08CA0.04
chr4:1022675522e-08T0.08
chr7:1143502972e-08T0.04
chr3:461827174e-08C2.3
chr6:319759014e-08A0.1
rs129320035e-08BCO1 - GANA0.57
chr19:19394395e-08TTTTTTTTTTTTG0.04
chr22:419283285e-08G2.37
rs78577303e-06JAK2C0.19
rs96169155e-06SHANK3?0.5
rs4978718e-06REXO2 - NXPE2P1G0.2
rs611993329e-06BLK-AS1 - LINC00208A0.44

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90129429Zorina-Lichtenwalter K202380,737157,458Genetic risk shared across 24 chronic pain conditions: identification and characterization with genomic structural equation modeling.
GCST90479424Verma A202471,811243,857Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90474012UK Biobank Whole-Genome Sequencing Consortium202542,885415,555Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90667790UK Biobank Whole-Genome Sequencing Consortium202542,885415,555Whole-genome sequencing of 490,640 UK Biobank participants.
GCST90479427Verma A202429,828285,840Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90691981Karczewski KJ202520,094372,332Pan-UK Biobank genome-wide association analyses enhance discovery and resolution of ancestry-enriched effects.
GCST90080405Backman JD202117,422365,539Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90084391Backman JD202117,422365,539Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90436657Zhou W201815,790365,819Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies.
GCST90080404Backman JD202115,502372,428Exome sequencing and analysis of 454,787 UK Biobank participants.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding1
Tier 2: splice/UTR0
Tier 3: regulatory0
Tier 4: intronic/intergenic19

MAF distribution

BucketVariants
common (>=0.05)6
low_freq (0.01-0.05)1
rare (<0.01)3
unknown10

Functional consequences

ConsequenceCount
unknown10
intergenic_variant5
intron_variant4
missense_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs731848802057755831G>A,T0.001intergenic_variantNKILA - LINC017428e-12Tier 4: intronic/intergenic
rs1903949161097056235C>T0intron_variantSLIT19e-12Tier 4: intronic/intergenic
rs570160466631388556C>A,T0.034intron_variantMICA-AS11e-11Tier 4: intronic/intergenic
rs560819378689092015A>G0.001intergenic_variantRN7SL336P - SRSF124e-11Tier 4: intronic/intergenic
chr2:704918889e-11Tier 4: intronic/intergenic
chr8:175741332e-09Tier 4: intronic/intergenic
rs7652522214103931872A>G0.05intron_variantTDRD91e-08Tier 4: intronic/intergenic
chr18:280757642e-08Tier 4: intronic/intergenic
chr3:500607532e-08Tier 4: intronic/intergenic
chr4:1022675522e-08Tier 4: intronic/intergenic
chr7:1143502972e-08Tier 4: intronic/intergenic
chr3:461827174e-08Tier 4: intronic/intergenic
chr6:319759014e-08Tier 4: intronic/intergenic
rs129320031681292633A>G,T0.4intergenic_variantBCO1 - GAN5e-08Tier 4: intronic/intergenic
chr19:19394395e-08Tier 4: intronic/intergenic
chr22:419283285e-08Tier 4: intronic/intergenic
rs785773095084049G>A,T0.05intron_variantJAK23e-06Tier 4: intronic/intergenic
rs96169152250679152T>C0.05missense_variantSHANK35e-06Tier 1: coding
rs49787111114476929A>G0.05intergenic_variantREXO2 - NXPE2P18e-06Tier 4: intronic/intergenic
rs61199332811573132C>T0.05intergenic_variantBLK-AS1 - LINC002089e-06Tier 4: intronic/intergenic

ClinVar germline variants

7 retrieved; paginated sample, class counts are floors:

3 uncertain significance, 2 pathogenic, 2 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
684430NM_005045.4(RELN):c.7456A>G (p.Ser2486Gly)RELNPathogenicno assertion criteria provided
989389NM_003177.7(SYK):c.1649C>A (p.Ser550Tyr)SYKPathogeniccriteria provided, single submitter
989237NM_003177.7(SYK):c.1350G>A (p.Met450Ile)SYKLikely pathogeniccriteria provided, single submitter
989387NM_003177.7(SYK):c.1024C>A (p.Pro342Thr)SYKLikely pathogeniccriteria provided, single submitter
2570675NM_015089.4(CUL9):c.7237C>T (p.Arg2413Trp)CUL9Uncertain significancecriteria provided, single submitter
2570677NM_015089.4(CUL9):c.2732C>T (p.Pro911Leu)CUL9Uncertain significancecriteria provided, single submitter
989236NM_003177.7(SYK):c.1057G>A (p.Ala353Thr)SYKUncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 3 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
SYKOrphanet:695807Immunodeficiency-systemic inflammation-lymphoma predisposition syndrome
RELNOrphanet:101046Epilepsy with auditory features
RELNOrphanet:89844Lissencephaly syndrome, Norman-Roberts type

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence3

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
SYKHGNC:11491ENSG00000165025P43405Tyrosine-protein kinase SYKclinvar
CUL9HGNC:15982ENSG00000112659Q8IWT3Cullin-9clinvar
RELNHGNC:9957ENSG00000189056P78509Reelinclinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
SYKTyrosine-protein kinase SYKNon-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR).
CUL9Cullin-9Core component of a Cul9-RING ubiquitin-protein ligase complex composed of CUL9 and RBX1.
RELNReelinExtracellular matrix serine protease secreted by pioneer neurons that plays a role in layering of neurons in the cerebral cortex and cerebellum by coordinating cell positioning during neurodevelopment.

Protein-family classification

Druggable: 1 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.33

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Kinase19.2×0.313
Transcription factor12.8×0.482
Other/Unknown10.6×0.914

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
SYKKinaseyes2.7.10.2Prot_kinase_dom, SH2, Ser-Thr/Tyr_kinase_cat_dom
CUL9Transcription factornoZnf_RING, IBR_dom, APC_su10/DOC_dom
RELNOther/UnknownnoEGF, Reeler_dom, EGF_extracell

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)3
unknown0

Top tissues across cohort

TissueCohort genes
leukocyte1
monocyte1
mononuclear cell1
left testis1
right frontal lobe1
right testis1
cerebellar vermis1
cerebellum1
olfactory bulb1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
SYK239broadmarkermonocyte, mononuclear cell, leukocyte
CUL9275ubiquitousmarkerright testis, left testis, right frontal lobe
RELN254broadmarkerolfactory bulb, cerebellar vermis, cerebellum

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
SYK5,172
RELN2,305
CUL91,551

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
SYKP4340593
CUL9Q8IWT34
RELNP785091

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 49. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Reelin signalling pathway1634.4×0.018RELN
FLT3 signaling through SRC family kinases1543.8×0.018SYK
Interleukin-2 signaling1317.2×0.018SYK
FCGR activation1292.8×0.018SYK
Interleukin-2 family signaling1211.5×0.018SYK
Role of LAT2/NTAL/LAB on calcium mobilization1200.3×0.018SYK
Signaling by CSF3 (G-CSF)1190.3×0.018SYK
Regulation of signaling by CBL1165.5×0.018SYK
DAP12 interactions1158.6×0.018SYK
Role of phospholipids in phagocytosis1152.3×0.018SYK
Platelet Aggregation (Plug Formation)1146.4×0.018SYK
Inactivation of CSF3 (G-CSF) signaling1146.4×0.018SYK
Integrin signaling1141.0×0.018SYK
Dectin-2 family1141.0×0.018SYK
Anti-inflammatory response favouring Leishmania parasite infection1131.3×0.018SYK
Leishmania parasite growth and survival1131.3×0.018SYK
DAP12 signaling1122.8×0.018SYK
FCERI mediated Ca+2 mobilization1119.0×0.018SYK
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers1119.0×0.018SYK
FCERI mediated MAPK activation1115.3×0.018SYK
FLT3 Signaling1115.3×0.018SYK
Parasite infection1115.3×0.018SYK
Leishmania phagocytosis1115.3×0.018SYK
Signaling by the B Cell Receptor (BCR)1115.3×0.018SYK
Interleukin-3, Interleukin-5 and GM-CSF signaling1105.7×0.018SYK
GPVI-mediated activation cascade1102.9×0.018SYK
FCGR3A-mediated IL10 synthesis197.6×0.019SYK
Fcgamma receptor (FCGR) dependent phagocytosis192.8×0.019SYK
Fc epsilon receptor (FCERI) signaling190.6×0.019SYK
C-type lectin receptors (CLRs)179.3×0.021SYK

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
spinal cord patterning15617.3×0.004RELN
positive regulation of interleukin-3 production15617.3×0.004SYK
regulation of superoxide anion generation15617.3×0.004SYK
regulation of arachidonate secretion15617.3×0.004SYK
positive regulation of lateral motor column neuron migration15617.3×0.004RELN
regulation of neutrophil degranulation12808.7×0.006SYK
cellular response to lectin12808.7×0.006SYK
leukocyte activation involved in immune response11872.4×0.006SYK
serotonin secretion by platelet11872.4×0.006SYK
beta selection11872.4×0.006SYK
lateral motor column neuron migration11872.4×0.006RELN
cerebral cortex tangential migration11404.3×0.006RELN
regulation of synaptic activity11404.3×0.006RELN
cellular response to molecule of fungal origin11404.3×0.006SYK
positive regulation of mast cell cytokine production11123.5×0.007SYK
NMDA glutamate receptor clustering11123.5×0.007RELN
regulation of platelet activation1936.2×0.007SYK
positive regulation of alpha-beta T cell proliferation1936.2×0.007SYK
postsynaptic density protein 95 clustering1936.2×0.007RELN
interleukin-3-mediated signaling pathway1802.5×0.007SYK
regulation of platelet aggregation1802.5×0.007SYK
gamma-delta T cell differentiation1702.2×0.007SYK
positive regulation of small GTPase mediated signal transduction1702.2×0.007RELN
receptor localization to synapse1702.2×0.007RELN
lymph vessel development1624.1×0.007SYK
neutrophil activation involved in immune response1624.1×0.007SYK
ventral spinal cord development1624.1×0.007RELN
positive regulation of gamma-delta T cell differentiation1624.1×0.007SYK
positive regulation of synapse maturation1624.1×0.007RELN
postsynaptic density assembly1624.1×0.007RELN

Therapeutics

Drugs indicated for this disease

13 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
AcetaminophenApproved (phase 4)
AdalimumabApproved (phase 4)
AspirinApproved (phase 4)
CamphorApproved (phase 4)
CapsaicinApproved (phase 4)
IbuprofenApproved (phase 4)
LidocaineApproved (phase 4)
MentholApproved (phase 4)
MethotrexateApproved (phase 4)
Methyl SalicylateApproved (phase 4)
NaproxenApproved (phase 4)
Penicillin VApproved (phase 4)
PrednisoneApproved (phase 4)
EtanerceptPhase 3 (in late-stage trials)

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 2

Druggability breadth: 2 of 3 evidence-associated genes (67%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
SYKFEDRATINIB

Top cohort targets by molecule count

SymbolMoleculesMax phase
SYK544
CUL900
RELN00

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
FEDRATINIB4SYK
NERATINIB4SYK
INFIGRATINIB PHOSPHATE4SYK
INFIGRATINIB4SYK
ENTRECTINIB4SYK
FOSTAMATINIB4SYK
CERITINIB4SYK
BOSUTINIB4SYK
GILTERITINIB4SYK
FOSTAMATINIB DISODIUM4SYK
PAZOPANIB4SYK
DASATINIB4SYK
ERLOTINIB4SYK
CRIZOTINIB4SYK
MIDOSTAURIN4SYK
IMATINIB4SYK
ENTOSPLETINIB3SYK
CEDIRANIB3SYK
QUERCETIN3SYK
LESTAURTINIB3SYK
FORETINIB2SYK
LUTEOLIN2SYK
REBASTINIB2SYK
APITOLISIB2SYK
CENISERTIB2SYK
ADAVOSERTIB2SYK
ILORASERTIB2SYK
R-3432SYK
FISETIN2SYK
TOP-12882SYK

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
SYK873Binding:863, Functional:10
CUL92Binding:2

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
SYK2.7.10.2, 2.7.12.1non-specific protein-tyrosine kinase, dual-specificity kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
SYK873

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
FEDRATINIB4SYK
NERATINIB4SYK
INFIGRATINIB PHOSPHATE4SYK
INFIGRATINIB4SYK
ENTRECTINIB4SYK
FOSTAMATINIB4SYK
CERITINIB4SYK
BOSUTINIB4SYK
GILTERITINIB4SYK
FOSTAMATINIB DISODIUM4SYK
PAZOPANIB4SYK
DASATINIB4SYK
ERLOTINIB4SYK
CRIZOTINIB4SYK
MIDOSTAURIN4SYK
IMATINIB4SYK
ENTOSPLETINIB3SYK
CEDIRANIB3SYK
QUERCETIN3SYK
LESTAURTINIB3SYK
FORETINIB2SYK
LUTEOLIN2SYK
REBASTINIB2SYK
APITOLISIB2SYK
CENISERTIB2SYK
ADAVOSERTIB2SYK
ILORASERTIB2SYK
R-3432SYK
FISETIN2SYK
TOP-12882SYK

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1SYK
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug2CUL9, RELN

Undrugged target profiles

2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
CUL92—
RELN0—

Clinical trials & evidence

Clinical trials

Clinical trials: 329.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified239
PHASE324
PHASE222
PHASE415
PHASE115
PHASE2/PHASE37
PHASE1/PHASE26
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00180206PHASE4UNKNOWNBirmingham Hip Resurfacing (BHR) Study: Implantation of a Hip Resurfacing Endoprosthesis
NCT00236366PHASE4COMPLETEDA Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, Compared With Placebo in Patients With Osteoarthritis
NCT00291915PHASE4UNKNOWNMulticenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis
NCT00510536PHASE4COMPLETEDTreatment of Mild to Moderate Joint Pain in Patients With Chronic Plaque Psoriasis Receiving Efalizumab
NCT00524160PHASE4COMPLETEDA Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or Osteoarthritis
NCT00696059PHASE4COMPLETEDHumira in Rheumatoid Arthritis - Do Bone Erosions Heal?
NCT01027286PHASE4COMPLETEDProspective Evaluation of Vitagel for Reduction in Blood Loss and Pain Following Unilateral Total Knee Arthroplasty
NCT01264965PHASE4TERMINATEDNon-cancer Pain and Cognitive Impairment: A Disabling Relationship
NCT01270620PHASE4COMPLETEDDesflurane or Propofol Anesthesia in Elderly Obese Patients Undergoing Total Knee Replacement
NCT01275014PHASE4UNKNOWNCorticosteroids as Additive in Temporomandibular Joint (TMJ) Arthrocentesis
NCT01414569PHASE4COMPLETEDDexamethasone for Pain After Shoulder Surgery
NCT02011464PHASE4COMPLETEDEvaluation Exparel Delivered in Knee Replacement
NCT02697955PHASE4COMPLETEDThe Effect of Subsartorial Saphenous Block on Postoperative Pain Following Major Ankle and Hind Foot Surgery
NCT02926651PHASE4WITHDRAWNSingle Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty
NCT03659318PHASE4COMPLETEDRobotic-Assisted Versus Conventional Total Knee Arthroplasty(TKA)
NCT05658575PHASE2/PHASE3RECRUITINGStudy of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT07580976PHASE3NOT_YET_RECRUITINGTru-Vu Wrist Positioning Aid Multi-Center Implementation Within NLHS
NCT00146367PHASE2/PHASE3COMPLETEDEvaluation of the Active Living Every Day Exercise Program for People With Arthritis
NCT00146393PHASE2/PHASE3COMPLETEDHealth Benefits of an Exercise Program for Adults With Arthritis
NCT00153309PHASE2/PHASE3COMPLETEDProgram Evaluation of People With Arthritis Can Exercise
NCT00153660PHASE3COMPLETEDCelecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients
NCT00153673PHASE3COMPLETEDEffect of Selective COX-2 Inhibition on Ulcer Healing
NCT00211718PHASE3UNKNOWNIntra-Articular Injection of Botulinum Toxin Type A for Shoulder Pain
NCT00252070PHASE2/PHASE3COMPLETEDFitness and Exercise for People With Arthritis
NCT00313365PHASE3WITHDRAWNSurgical Lavage vs Serial Needle Aspiration for Infected Joints
NCT00365313PHASE3COMPLETEDPreventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib
NCT00521963PHASE2/PHASE3WITHDRAWNIntraarticular Injection of Infliximab
NCT00526201PHASE3COMPLETEDHelp Arthritis With Exercise in West Virginia
NCT00526435PHASE3COMPLETEDEvaluation of Walk With Ease in Arthritis
NCT00646178PHASE3COMPLETEDStudy of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy
NCT00733902PHASE3COMPLETEDTanezumab in Osteoarthritis of the Knee
NCT00744471PHASE3COMPLETEDTanezumab in Osteoarthritis Of The Hip
NCT00765362PHASE3COMPLETEDMobile - Bearing Knee Study
NCT00784277PHASE3COMPLETEDA Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
NCT00809354PHASE3TERMINATEDLong-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
NCT00830063PHASE3COMPLETEDTanezumab In Osteoarthritis Of The Knee (2)
NCT01004432PHASE3COMPLETEDGolimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
NCT01089725PHASE3TERMINATEDEfficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study
NCT01094886PHASE3COMPLETEDSwitching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
NCT01615991PHASE3COMPLETEDMulticentre Canadian Study to Measure the Safety and Efficacy of Radiosynoviorthesis

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
SUMATRIPTAN43
ADALIMUMAB42
BETAMETHASONE42
DEXAMETHASONE42
FENTANYL42
NAPROXEN42
TIZANIDINE42
ABATACEPT41
ACETAMINOPHEN41
BACLOFEN41
BUPIVACAINE41
CALCIPOTRIENE41
CITRIC ACID41
CYCLOBENZAPRINE41
DESFLURANE41
DICLOFENAC41
ESFLURBIPROFEN41
ETORICOXIB41
FLURBIPROFEN41
GOLIMUMAB41
MELOXICAM41
MENTHOL41
METHOTREXATE41
NIACINAMIDE41
PRILOCAINE41
PROPOFOL41
PYRIDOXINE41
RETINOL41
RIVAROXABAN41
SODIUM CITRATE41

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 71

This page pulls from 71 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot